Heart failure policy and practice in Europe
Heart failure policy and practice in Europe aims to support advocates with clear outline of policy issues and best practice in heart failure across 11 European countries.
Find out more
Heart failure and COVID‑19
With heart failure a high-risk pre-existing condition and heart damage a consequence of COVID-19, what does the pandemic mean for heart failure care?
Find out more
Heart failure and health system sustainability
A European case study outlining how prioritising heart failure can help to build resilient and sustainable healthcare systems.
Find out more
heart graphic

Helping advance meaningful policy change on heart failure

The Heart Failure Policy Network is an independent, multidisciplinary platform of healthcare professionals, advocacy groups and policymakers from across Europe.

We aim to raise awareness of the unmet needs surrounding heart failure and its care, and to help drive meaningful changes in policy and practice.

Find out more
Latest
The unique opportunities for heart failure specialists in England’s restructured cardiac services
7 May 2021

Dr Simon Williams examines the future of cardiac services in England, and how heart failure specialists can have a vital role.

Read article
Latest
Freedom from heart failure: reimagining cardiac services in England
30 April 2021

Join the British Society for Heart Failure and the Heart Failure Policy Network for an in-depth discussion of the future of cardiac services in England.

Read article
Latest
Reducing heart failure hospitalisations is vital to health system sustainability
16 March 2021

HFPN Network Director Ed Harding presented a case study on preventing hospital admissions in heart failure at the PHSSR Global Summit.

Read article
heart failure graphic
What is heart failure?

Affecting at least 15 million adults in Europe, heart failure is a common but complex clinical syndrome that occurs when the heart is unable to pump enough blood to meet body’s needs.

Its prevalence is expected to rise due to population ageing and improved survival rates for other long-term conditions, including cardiovascular diseases.

Find out more
The Heart Failure Policy Network is made possible with financial support from AstraZeneca, Vifor Pharma and Novartis Pharma. The content produced by the Network is non-promotional and not biased to any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members.